CSIMarket Company Name, Ticker, Customers, else..
 
Lyra Therapeutics Inc   (NASDAQ: LYRA)
 
Price: $0.2000 $0.01 5.263%
Day's High: $0.20000000298023224 Week Perf: 0.00
Day's Low: $ 0.20 30 Day Perf: -28.57 %
Volume (M): 110 52 Wk High: $ 52.00
Volume (M$): $ 0 52 Wk Avg: $2.43
Open: $0.20 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 2
 Employees 27
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 0

Business Description


Lyra Therapeutics Inc. is a biotechnology company that focuses on developing novel therapies for ear, nose, and throat (ENT) conditions. The company's main expertise lies in the field of localized drug delivery, specifically using its proprietary Xtampza® technology platform.

Lyra Therapeutics aims to provide effective treatment options for various ENT conditions, including chronic rhinosinusitis (CRS). Their Xtampza technology enables the controlled and sustained release of therapeutics directly to the affected areas, allowing for localized and long-lasting drug delivery.

By utilizing their innovative approach, Lyra Therapeutics aims to improve patient outcomes and address the limitations of existing treatments for ENT conditions. Their research and development efforts are focused on advancing the clinical development of their pipeline products, with the ultimate goal of bringing novel therapies to patients in need.


   Company Address: 480 Arsenal Way Watertown 2472 MA
   Company Phone Number: 393-4600   Stock Exchange / Ticker: NASDAQ LYRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APYX   -6.21%    
ESTA   -2.54%    
INMD   -0.47%    
MDXG        4.18% 
RCEL   -10.79%    
SRTS   -2.61%    
• View Complete Report
   



Clinical Study

Lyra Therapeutics Reaches Clinical Milestone with Full Enrollment in Key ENLIGHTEN 2 Trial for LYR-210 Pioneering Hop...

Published Tue, Oct 15 2024 11:00 AM UTC

In a significant advancement in the treatment landscape for chronic rhinosinusitis (CRS), Lyra Therapeutics, Inc. (Nasdaq: LYRA), a pioneering clinical-stage biotechnology company, has officially announced the full enrollment of participants in its pivotal Phase 3 ENLIGHTEN 2 clinical trial. This trial is crucial for evaluating LYR-210, a cutting-edge bioresorbable nasal imp...
Clinical Study

Lyra Therapeutics Unveils Pioneering Results for Chronic Rhinosinusitis Treatment at Major Otolaryngology Conferenc...

Published Fri, Sep 27 2024 11:00 AM UTC

: Current treatments for chronic rhinosinusitis (CRS) often necessitate systemic administration of anti-inflammatory drugs or invasive surgical interventions. Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company, is pioneering novel therapeutic approaches designed to provide sustained localized treatment for CRS. The company recently announced that ...
Clinical Study

Lyra Therapeutics Adopts Stringent Measures to Preserve Capital Amidst Challenging Market Conditions

Published Tue, May 21 2024 1:14 PM UTC

In an effort to navigate the challenging landscape of the pharmaceutical industry, Lyra Therapeutics, a leading biopharmaceutical company based in Watertown, Massachusetts, has recently announced a series of cost-cutting measures. These measures include a significant reduction of approximately 75% of its workforce and the implementation of other strategies aimed at preservin...
Clinical Study

The Road Not Taken: Lyra Therapeutics’ Unexpected Outcome from Phase 3 Clinical Trial and its Ripple Effect.

Published Mon, May 6 2024 11:59 AM UTC

In an unexpected turn of events, Lyra Therapeutics reported that its Phase 3 ENLIGHTEN 1 Trial for LYR-210 failed to meet its primary endpoint. LYR-210, an innovative therapy for chronic rhinosinusitis, a debilitating condition characterized by inflammation of the nose and sinuses, has been under research and development for years. The trial, which sought to evaluate LYR-210...
Shares

Lyra Therapeutics Moves towards Expansion: Grants Inducement Awards to New Employees

Published Fri, Apr 26 2024 8:51 PM UTC



In a move highlighting its commitment towards growth and innovation, Lyra Therapeutics, a clinical-stage biotech company focused on developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS), has granted inducement stock options to a group of new non-executive employees. This strategic initiative aims to attract top talent and fos...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.78
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.24
Working Capital Ratio 1.27
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -19.86 $
Revenues (TTM) 0.26 $
Cash Flow (TTM) -
Cash 10.23 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 14,741
Net Income per Employee (TTM) -1,071,074
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -101685.71 %
Net Margin (MRQ) -99300 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Lyra Therapeutics Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.